You are here
DEKK-TEC INC
UEI: E9MHC27T2XK3
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies
Amount: $1,211,230.00Abstract – The goal of this Phase II clinical trial application will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) as anticancer therapy for adolescents and young adu ...
SBIRPhase II2018Department of Health and Human Services National Institutes of Health -
A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS
Amount: $286,588.00The goal of this Phase I clinical trial will be to document safety and potential usefulness ofdemethylcholesteryloxycarbonylpenclomedineDM CHOC PENin combination with de escalating doses of whole brai ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Phase I Clinical trial with Demethyl cholesteryloxycarbonylpenclomedine DM CHOC PEN in Children with Cancer Involving the CNS
Amount: $230,724.00DESCRIPTION provided by applicant The primary goal of this Phase I pediatric oncology clinical trial will be to evaluate the safety and use of demethyl cholesteryloxycarbonylpenclomedine DM CH ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica
Amount: $1,161,453.00DESCRIPTION (provided by applicant): The principal goal of this research project will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a polychlorinated cholesterol carbo ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Camptothecin Analogs for Cancer Therapy
Amount: $837,217.00DESCRIPTION (provided by applicant): 7-Butyl-10-aminocamptothecin (BACPT), as a water-soluble dipeptide pro-drug - BACPTDP, is a novel camptothecin analog that has increased activity in hypoxic/acidic ...
SBIRPhase II2010Department of Health and Human Services National Institutes of Health -
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr
Amount: $272,657.00DESCRIPTION (provided by applicant): The object of the proposed research is to conduct a Phase 1 clinical trial with 4-demethyl-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a carbonate derivative ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Camptothecin Analogs for Cancer Therapy
Amount: $158,895.00DESCRIPTION (provided by applicant): 7-butyl-10-aminocamptothecin (BACPT) and its water-soluble dipeptide pro-drug, are novel camptothecins that were designed to be used in the treatment of childhood ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
SBIR TOPIC 232 MANUFACTURE OF 4-DEMETHYL 4-CHOLESTEROLYL-PENCLOMEDINE
Amount: $150,000.00N/A
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
Clinical Development of 4-Hydroperoxyifosfamide
Amount: $539,124.00DESCRIPTION (provided by applicant): 4-Hydroperoxyifosfamide (HOO-IFOS) is a stable, pre-activated form (peroxide) of 4-HO-IFOS, the initial metabolite of Ifosfamide (IFOS). Under physiological condit ...
SBIRPhase II2006Department of Health and Human Services National Institutes of Health -
A-007: Immune Modulation of HPV- Associated Neoplasia
Amount: $2,300,490.00DESCRIPTION (provided by applicant): 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) was originally developed as an immune modulator of immune deficiency associated cancerous growths. In ...
SBIRPhase II2005Department of Health and Human Services National Institutes of Health